A multicenter retrospective study in China evaluates the use of efgartigimod for treating juvenile myasthenia gravis, providing insights into its effectiveness and safety profile. This research contributes to the growing body of evidence supporting efgartigimod's role in managing this rare neuromuscular disorder.
experience using efgartigimod to treat juvenile myasthenia gravis in china a multicenter retrospective study
Original title: “Experience Using Efgartigimod to Treat Juvenile Myasthenia Gravis in China: A Multicenter Retrospective Study.”